BioWorld Asia

Oct. 5, 2005

Scientists Probe Signature' Of Cancer Genetic Damage

NatImmune, Enzon Enter Deal On Recombinant MBL

Closing In On First Revenues, Phoqus Seeking IPO On Aim

MMI Raises £10M For Genvax's Clinical Studies Of Vaccines

Other News To Note

Karo Bio Seeking SEK280M In Discounted Rights Issue

Karo Bio AB is seeking SEK280 million (US$35.9 million) in a discounted rights issue to fund its switch from early stage discovery to clinical development. (BioWorld International) Read More

SkyePharma Raising Funds After Scuttled Partner Deal

Today's news in brief

BioWorld

BioWorld briefs for March 12, 2026.

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...